5.4 Hematology, Anemias, and Blood Component Therapy

5.4 Hematology, Anemias, and Blood Component Therapy

Hematological homeostasis is essential for tissue oxygenation, hemostasis, and immune defense. In acute and medical-surgical nursing, evaluating complete blood counts, distinguishing between diverse morphological classes of anemia, executing bleeding precautions in severe thrombocytopenia, and safely administering allogeneic blood components represent essential clinical competencies. Errors during blood product administration carry catastrophic, potentially fatal consequences, making absolute adherence to evidence-based nursing protocols non-negotiable.

---

Normal Hematological Biomarkers & Morphological Classifications

Understanding normal reference parameters provides the benchmark for identifying hematological pathology:

                                [ Morphological Classification of Anemias ]
                                                    │
         ┌──────────────────────────────────────────┼──────────────────────────────────────────┐
         ▼                                          ▼                                          ▼
   [ MICROCYTIC ]                             [ NORMOCYTIC ]                             [ MACROCYTIC ]
     MCV < 80 fL                               MCV 80-100 fL                              MCV > 100 fL
- Iron Deficiency Anemia                   - Acute Hemorrhage                        - Pernicious Anemia (B12)
- Thalassemia Minor/Major                  - Anemia of Chronic Disease               - Folate Deficiency
- Sideroblastic Anemia                     - Aplastic Anemia                         - Liver Disease / Alcoholism
- Lead Poisoning                           - Hemolytic Anemias (Sickle Cell)         - Chemotherapy (Hydroxurea)

---

The Major Clinical Anemias

1. Iron Deficiency Anemia (Microcytic, Hypochromic)

• Pathophysiology: Inadequate systemic iron availability impairs heme synthesis. Because hemoglobin imparts red pigmentation and cytoplasmic volume to erythrocytes, circulating red blood cells become abnormally small (microcytic, MCV < 80 fL) and pale (hypochromic, low MCHC).
• Common Etiologies: Chronic occult gastrointestinal blood loss (peptic ulcer disease, colon malignancy, diverticulosis), excessive menstrual bleeding (menorrhagia), impaired gastrointestinal absorption (celiac disease, post-gastrectomy, bariatric bypass of the duodenum), and inadequate dietary intake during periods of accelerated physiological demand (pregnancy, lactation, infancy).
• Diagnostic Hallmarks: Decreased serum ferritin (< 15 ng/mL; the most specific indicator of total body iron store depletion), decreased serum iron, markedly elevated Total Iron-Binding Capacity (TIBC), and transferrin saturation < 15%.
• Clinical Manifestations: Generalized fatigue, exertional dyspnea, pallor, tachycardia, irritability, angular cheilitis (painful fissures at the labial commissures), atrophic glossitis (smooth, beefy-red tongue), brittle spoon-shaped nails (koilonychia), and pica (compulsive ingestion of non-nutritive substances such as ice [pagophagia], clay, or starch).

Pharmacological Administration & Patient Education for Oral Iron (Ferrous Sulfate)

• Timing and Gastric Environment: Administer on an empty stomach (1 hour before or 2 hours after meals). Duodenal absorption of non-heme iron is highest in an acidic gastric milieu.
• Enhancing Absorption with Vitamin C: Co-administer each oral iron dose with a source of ascorbic acid (Vitamin C), such as a full glass of orange juice or a 500 mg vitamin C tablet. Ascorbic acid reduces ferric (Fe3+) iron to soluble ferrous (Fe2+) iron, significantly enhancing brush-border mucosal uptake.
• Substances that Inhibit Iron Absorption (MANDATORY TO AVOID CONCURRENTLY):
  • Dairy products, cow's milk, and calcium supplements: Calcium competitively binds and precipitates iron.
  • Antacids, Proton Pump Inhibitors (PPIs), and H2-blockers: Suppress gastric acidity, preventing iron ionization.
  • Tea (tannins) and coffee (polyphenols): Form insoluble chelate complexes with iron.
  • Rule: Separate the ingestion of these substances from oral iron by at least 2 hours.
• Anticipated Harmless Gastrointestinal Effects: Reassure the patient that iron therapy universally turns stools dark green or black and tarry. Warn them of this expected finding so they do not mistake it for melena (upper GI hemorrhage). Common adverse effects include constipation, epigastric burning, and nausea. Recommend high-fiber diet, abundant fluids, and a stool softener (docusate).
• Liquid Iron Formulations: Liquid iron solutions readily bind to dental enamel, causing permanent, dark brownish-black staining of teeth. Liquid iron MUST be diluted with water or fruit juice, ingested through a straw placed past the teeth, and followed immediately by thorough mouth rinsing with water.

2. Sickle Cell Disease & Vaso-Occlusive Crisis

• Pathophysiology: Autosomal recessive genetic disorder characterized by a point mutation on chromosome 11, substituting valine for glutamic acid at the sixth position of the beta-globin chain, forming hemoglobin S (HbS). Under conditions of deoxygenation, dehydration, acidosis, or hypothermia, HbS molecules polymerize into rigid, insoluble crystalline rods. This distorts the flexible, biconcave erythrocyte into an inflexible, crescent- or sickle-shaped cell with a markedly shortened lifespan (hemolytic anemia, surviving only 10 to 20 days versus 120 days for normal erythrocytes).
• Vaso-Occlusive Crisis (VOC / "Pain Crisis"): Rigid sickled erythrocytes aggregate and adhere to vascular endothelium in capillary beds and post-capillary venules, causing microvascular occlusion, tissue hypoperfusion, severe localized ischemia, infarction, and excruciating, unremitting bone and joint pain.
• Precipitating Triggers: Dehydration, hypoxia, high altitude, systemic infection/fever, cold environmental exposure, strenuous physical exertion, and metabolic acidosis.

The Emergency HOP Resuscitation Protocol for Vaso-Occlusive Crisis

[ Emergency Resuscitation for Sickle Cell Vaso-Occlusive Crisis: The HOP Protocol ]
     │
     ├─► H — HYDRATION (First Priority)
     │   - Aggressive IV hypotonic/isotonic fluids (D5W, 0.45% NS) at 1.5 to 2x maintenance
     │   - Decreases blood viscosity, reverses erythrocyte sickling, flushes renal tubules
     │
     ├─► O — OXYGENATION
     │   - Administer supplemental O2 if SpO2 < 95% or patient is hypoxic
     │   - Prevents further secondary sickling of circulating erythrocytes
     │
     └─► P — PAIN RELIEF (Aggressive & Around-the-Clock)
         - Parenteral IV Opioids (Morphine, Hydromorphone) around-the-clock or via PCA
         - NEVER administer Meperidine (Demerol) — risk of fatal seizures from normeperidine

1. H — Hydration (First Priority): Aggressive fluid therapy is paramount. Rapidly infuse hypotonic or isotonic intravenous crystalloids (such as 0.45% Normal Saline or 5% Dextrose in 0.45% NS) at 1.5 to 2 times baseline maintenance fluid requirements (typically 150 to 200 mL/hr in adults). Rehydration hemodilutes the blood, lowers serum osmolarity, reduces blood viscosity, reverses reversible red cell deformation, and mobilizes microvascular sludging.
2. O — Oxygenation: Provide supplemental oxygen via nasal cannula to maintain SpO2 >= 95%. While oxygen cannot reverse cells already sickled in stagnant microvascular beds, optimizing arterial PO2 prevents secondary sickling of circulating cells and protects ischemic tissues.
3. P — Pain Relief (Analgesia): Severe ischemic bone and joint pain is excruciating and constitutes a true medical emergency. Administer intravenous opioids (Morphine Sulfate or Hydromorphone [Dilaudid]) delivered around-the-clock (ATC) on a fixed schedule or via Patient-Controlled Analgesia (PCA). Never administer analgesics on a "PRN" (as-needed) basis during acute crisis, as this results in subtherapeutic troughs and uncontrolled breakthrough pain.
   • CRITICAL CONTRAINDICATION: Meperidine (Demerol) is STRICTLY CONTRAINDICATED in sickle cell disease! Repeated administration leads to rapid systemic accumulation of its active neurotoxic metabolite, normeperidine, which cannot be cleared efficiently and precipitates severe central nervous system irritability, tremors, myoclonus, and fatal grand mal seizures.
4. Additional Supportive Interventions: Maintain warm ambient room temperatures; apply warm blankets (never cold packs or ice, which induce fierce vasoconstriction and amplify sickling); bed rest to minimize metabolic oxygen consumption; venous thromboembolism (VTE) prophylaxis; prophylactic vaccinations (Pneumococcal, Meningococcal, Hib) due to early functional asplenia caused by repetitive splenic micro-infarctions.

3. Pernicious Anemia & Vitamin B12 Deficiency (Macrocytic, Megaloblastic)

• Pathophysiology: Vitamin B12 (cobalamin) is an essential coenzyme required for DNA synthesis in rapidly dividing hematopoietic precursors and for myelin sheath maintenance throughout the central and peripheral nervous systems. Dietary B12 binds to Intrinsic Factor (IF), a glycoprotein secreted exclusively by gastric parietal cells, allowing receptor-mediated absorption in the terminal ileum.
• Pernicious Anemia: An autoimmune disorder characterized by autoantibodies against gastric parietal cells and intrinsic factor, causing chronic atrophic gastritis and absolute intrinsic factor deficiency. Without intrinsic factor, dietary B12 cannot be absorbed regardless of oral intake.
• Diagnostic Findings: Macrocytic megaloblastic anemia (MCV > 100 fL), hypersegmented neutrophils (> 5 lobes) on peripheral blood smear, low serum cobalamin (< 200 pg/mL), elevated serum methylmalonic acid (MMA) and homocysteine levels, and positive anti-intrinsic factor antibodies.

The Critical Clinical Distinction: Vitamin B12 vs. Folic Acid Deficiency

• Pharmacological Treatment: Lifelong Intramuscular (IM) Cyanocobalamin (Vitamin B12) injections. Typical schedule: 1,000 mcg IM daily for 1 to 2 weeks, then weekly until hematological indices normalize, followed by 1,000 mcg IM monthly for the remainder of the patient's life. Because intrinsic factor is permanently absent, standard oral B12 cannot correct true pernicious anemia (unless massive pharmacological oral doses of 1,000 to 2,000 mcg/day are administered via passive mass-action diffusion under close surveillance).

---

Severe Thrombocytopenia & Bleeding Precaution Bundles

Thrombocytopenia is defined as a circulating platelet count < 150,000 /mcL. As platelet counts decline, clinical bleeding risks escalate predictably:

[ Platelet Count ]          [ Bleeding Risk Stratification ]        [ Clinical Nursing Mandates ]
50,000 - 100,000 /mcL       Prolonged bleeding with major trauma     Monitor surgical sites, avoid NSAIDs
20,000 - 50,000 /mcL        Bleeding with minor trauma / petechiae   Initiate Bleeding Precautions Bundle
< 20,000 /mcL               Spontaneous, life-threatening hemorrhage Critical bed rest, neuro checks q2-4h
< 10,000 /mcL               Immediate fatal hemorrhage risk          Prophylactic Platelet Transfusion stat

The Comprehensive Nursing Bleeding Precaution Bundle

Instituted immediately whenever a patient's platelet count drops below 50,000 /mcL (and enforced with extreme vigilance when < 20,000 /mcL):

1. Invasive Procedure Restrictions:
   • Strictly avoid Intramuscular (IM) injections. All injections must be converted to oral or intravenous routes. If a subcutaneous injection is clinically unavoidable, use the smallest possible needle gauge (25G to 27G) and maintain manual pressure for at least 5 minutes.
   • Strictly avoid arterial punctures unless absolutely life-sustaining.
   • Following any routine venipuncture or IV catheter discontinuation, apply continuous, direct manual pressure over the puncture site for at least 5 to 10 minutes (longer if co-existing coagulopathy exists). Never rely on a simple adhesive bandage.
   • Consolidate lab draws to minimize venipunctures.
2. Avoidance of Mucosal Trauma:
   • STRICT PROHIBITION OF RECTAL INTERVENTIONS: Never obtain rectal temperatures. Strictly avoid rectal suppositories, enemas, and digital rectal examinations. Mucosal micro-tears in the rectal vault can trigger uncontrollable, fatal hemorrhage.
   • Oral Hygiene: Instruct patient to use an ultra-soft bristle toothbrush or disposable foam swabs (toothette). Strictly avoid dental flossing. Lubricate lips with water-soluble petroleum jelly to prevent cracking.
   • Shaving: Use ONLY an electric razor. Traditional safety razors and straight blades are strictly prohibited.
   • Instruct patient to avoid vigorous nose-blowing. If epistaxis occurs, seat patient upright, tilt head slightly forward, and pinch the soft anterior cartilaginous portion of the nose firmly for 10 to 15 minutes.
3. Gastrointestinal & Fall Safeguards:
   • Administer stool softeners (e.g., docusate sodium) daily to prevent constipation and straining during defecation (the Valsalva maneuver dramatically spikes intracranial and hemorrhoidal venous pressures).
   • Implement high fall-risk precautions: clear clutter, ensure well-lit rooms, provide non-skid footwear, supervise all ambulation.
   • Avoid medications that compromise platelet aggregation: Aspirin, NSAIDs (ibuprofen, naproxen), and antiplatelet agents.
4. Neurological Surveillance:
   • Perform serial neurological examinations every 2 to 4 hours. Intracranial hemorrhage is the leading cause of death in severe thrombocytopenia.
   • Immediately investigate any new-onset headache, visual blurriness, unequal pupillary responses, confusion, somnolence, projectile vomiting, or sudden sensory/motor deficits.

---

Blood Component Administration Protocols

Allogeneic blood transfusion is a specialized transplantation procedure requiring strict adherence to verification and administration protocols:

Characteristics of Blood Components

• Packed Red Blood Cells (PRBCs): Concentrated erythrocytes with approximately 80% of plasma removed. Indicated to restore oxygen-carrying capacity in severe anemia or active hemorrhage. One unit (~250 to 300 mL) typically raises an adult's Hemoglobin by 1.0 g/dL and Hematocrit by 3%.
• Platelets: Concentrated thrombocytes indicated for severe thrombocytopenia with active bleeding or prophylactic coverage before surgery (< 50,000/mcL). Infused rapidly over 15 to 30 minutes through a dedicated platelet administration set with a special filter (do not chill; store at room temperature with gentle continuous agitation).
• Fresh Frozen Plasma (FFP): Liquid plasma containing all soluble coagulation factors. Indicated for active bleeding in multi-factor coagulopathies, severe liver disease, and rapid reversal of warfarin toxicity. Infused over 30 to 60 minutes.
• Cryoprecipitate: Insoluble concentrate rich in Fibrinogen, Factor VIII, Factor XIII, and von Willebrand Factor. Indicated for severe hypofibrinogenemia (< 100 mg/dL) or massive hemorrhage.

Pre-Transfusion Verification & Equipment Standards

[ Blood Administration Safeguards ]
     │
     ├─► VASCULAR ACCESS: 18-gauge or 20-gauge IV catheter (22G acceptable in frail elderly)
     │
     ├─► TUBING & FILTER: Dedicated Y-type blood tubing with inline 170-260 micron microaggregate filter
     │
     ├─► COMPATIBLE FLUID: Primed ONLY with 0.9% Normal Saline (Fatal: D5W = Hemolysis, LR = Clotting!)
     │
     ├─► TWO-NURSE INDEPENDENT BEDSIDE VERIFICATION:
     │   - Compare Blood Bag Label, Medical Order, and Patient ID Band
     │   - 2 Identifiers: Patient Full Name & Medical Record Number
     │   - Unit Identification Number & ABO / Rh Compatibility
     │   - Expiration Date and Time
     │
     ├─► INITIAL 15-MINUTE VIGILANCE:
     │   - Start infusion slowly: ~2 mL/min (or ≤ 25-50 mL over first 15 min)
     │   - Registered Nurse MUST remain continuously at bedside for first 15 minutes
     │
     └─► 4-HOUR COMPLETION LIMIT:
         - Unit MUST finish within 4 hours of leaving blood bank (Bacterial proliferation risk)

1. Vascular Access: Large-bore peripheral intravenous catheter is preferred—18-gauge or 20-gauge—to prevent mechanical shear stress and lysis of erythrocytes during infusion. A 22-gauge catheter may be used in frail adults or pediatric patients if infused slowly via an electronic infusion pump approved for blood products.
2. The Dual-Nurse Independent Bedside Verification Protocol:
   • The leading cause of fatal acute hemolytic transfusion reactions is human clerical error (mislabeled specimens or infusing blood into the wrong patient).
   • Two licensed healthcare providers (at least one must be a registered nurse) must simultaneously verify the patient and the blood product at the patient's immediate bedside:
     1. Patient's full legal name and unique hospital Medical Record Number (MRN) on the patient's wristband, matching the blood bank requisition form and the electronic medical administration record.
     2. Blood unit donor identification number printed on the blood bag, matching the crossmatch tag.
     3. ABO blood group and Rh type of the recipient and the donor unit.
     4. Expiration date and time of the blood unit.
     5. Visual inspection of the blood unit: Check for dark purplish discoloration, gross clumping, gas bubbles (signaling bacterial contamination), or leaks. Return immediately to the blood bank if any abnormality is observed.
3. Tubing and Priming Solution:
   • Must use dedicated Y-type blood administration tubing equipped with an inline 170- to 260-micron microaggregate filter designed to trap cellular debris, fibrin clots, and leukocyte aggregates.
   • THE ONLY COMPATIBLE FLUID IS 0.9% NORMAL SALINE (0.9% NaCl)!
   • FATAL INCOMPATIBILITIES:
     • Never prime or flush blood tubing with 5% Dextrose (D5W) or hypotonic solutions! Hypotonic glucose solutions cause osmotic swelling, clumping, and massive intravascular hemolysis of erythrocytes inside the tubing.
     • Never prime or flush with Lactated Ringer's (LR)! Lactated Ringer's contains ionized calcium. The calcium overcomes the citrate anticoagulant in the blood preservation bag, triggering massive clot formation within the IV tubing and vascular access.
     • Never piggyback or co-infuse ANY medications into a blood line! Secondary lines can precipitate hemolysis or medication binding.
4. Timing and Rate Constraints:
   • Blood must be initiated within 30 minutes of release from the blood bank refrigerator. If administration cannot begin within 30 minutes, return the unit immediately to the blood bank.
   • The Critical First 15 Minutes: Initiate the transfusion at a slow rate of 2 mL/min (or approximately 25 to 50 mL over the first 15 minutes). The registered nurse MUST remain at the patient's immediate bedside for the entire first 15 minutes of the transfusion. The most lethal immunological reactions (acute hemolytic and severe anaphylactic reactions) manifest within the first 50 mL of transfused blood.
   • If no adverse reactions occur after 15 minutes, re-evaluate vital signs and increase the flow rate to the prescribed speed (typically infusing one unit of PRBCs over 1.5 to 2 hours in a non-bleeding adult).
   • The Strict 4-Hour Time Limit: A unit of PRBCs must be completely infused within a maximum of 4 hours from the time it was removed from the blood bank refrigerator. Blood warm at ambient room temperatures promotes explosive bacterial proliferation. If blood remains in the bag at the 4-hour mark, stop the infusion immediately, disconnect the unit, and return the remaining volume to the blood bank.

Transfusion Reactions: Classification, Recognition, and Emergency Management

When an adverse transfusion reaction occurs, the nurse's immediate actions dictate the patient's survival.

Clinical Matrix of Acute Transfusion Complications

---

The Step-by-Step Universal Emergency Transfusion Reaction Protocol

If any signs of an adverse reaction develop—even mild fever or slight chest tightness—the registered nurse must execute this precise sequential intervention protocol without hesitation:

                                  [ Suspected Transfusion Reaction ]
                                                  │
                                    1. STOP TRANSFUSION IMMEDIATELY
                                                  │
                                    2. DISCONNECT TUBING AT IV HUB
                                       (Never Flush Remaining Blood!)
                                                  │
                                    3. HANG FRESH 0.9% NORMAL SALINE
                                       (Using Entirely New IV Tubing)
                                                  │
                                    4. ASSESS VITALS & PATIENT STATUS
                                       (Airway, Breathing, Vitals, Urine)
                                                  │
                                    5. NOTIFY PRESCRIBER & BLOOD BANK
                                                  │
                         ┌────────────────────────┴────────────────────────┐
                         ▼                                                 ▼
           [ SPECIMEN COLLECTION & DISPATCH ]                [ RESUSCITATION & DOCUMENTATION ]
           - Send blood bag, attached tubing, & tag          - Administer ordered emergency meds
             back to Blood Bank                                (Epinephrine, Antihistamines, Diuretics)
           - Collect post-reaction blood sample              - Monitor urine output & color for hemolysis
           - Collect first-voided urine sample               - Document timeline, vitals, & interventions

1. STOP THE TRANSFUSION IMMEDIATELY: The total volume of incompatible blood transfused directly correlates with the severity of hemolysis, renal failure, and mortality.
2. DISCONNECT THE BLOOD TUBING DIRECTLY AT THE IV CATHETER HUB: DO NOT simply turn off the roller clamp or press pause on the infusion pump while leaving the blood tubing connected. If normal saline from the Y-tubing bag is flushed through the existing line, the remaining 20 to 30 mL of incompatible or contaminated blood sitting in the tubing will be flushed directly into the patient's vein!
3. ASPIRATE AND CONNECT FRESH NORMAL SALINE: Aspirate 3 to 5 mL of blood from the IV catheter hub to clear residual transfusate. Connect a new, sterile IV administration set primed with fresh 0.9% Normal Saline directly to the catheter hub, and infuse saline at a slow keep-vein-open (KVO) rate (or wide open if the patient is hypotensive) to preserve vascular access for emergency resuscitation medications.
4. ASSESS PATIENT & VITAL SIGNS: Immediately obtain a complete set of vital signs (BP, HR, RR, SpO2, Temperature). Auscultate lung fields for crackles, stridor, or wheezing. Assess for facial edema, urticaria, flank tenderness, and mental status changes.
5. NOTIFY THE HEALTHCARE PROVIDER & BLOOD BANK: Communicate the clinical findings using the SBAR (Situation, Background, Assessment, Recommendation) framework. Contact the hospital blood bank immediately to report the adverse reaction.
6. BEDSIDE RE-VERIFICATION: Re-check all identification tags, unit labels, recipient medical record numbers, and compatibility tags at the bedside to determine if a clerical error occurred.
7. DISPATCH BLOOD CONTAINER & SAMPLES TO BLOOD BANK: Place the discontinued blood bag, along with all attached tubing, filters, and crossmatch tags, into a biohazard transport container and send it immediately to the blood bank for repeat serological testing, antibody screening, and microbiological cultures.
8. COLLECT POST-REACTION BLOOD & URINE SAMPLES: Draw post-reaction blood samples from the opposite arm for repeat type and crossmatch, direct antiglobulin (Coombs) test, complete blood count, and free serum hemoglobin. Collect the first-voided urine specimen and send it immediately to the laboratory to test for hemoglobinuria (presence of free hemoglobin from intravascular erythrocyte destruction, confirming an acute hemolytic reaction).
9. DOCUMENT THOROUGHLY: Document the exact time the transfusion was initiated and stopped, the volume of blood infused, initial and post-reaction vital signs, clinical manifestations, notifications made, emergency medications administered, laboratory specimens collected, and the patient's clinical trajectory in the permanent electronic health record.